Preoperative [68Ga]Ga-PSMA-11 PET/CT in patients with suspected brain tumors of glial origin – imply on diagnosis and early prognosis - a prospective clinical trial DOI Creative Commons
Kacper Pełka, Kacper Koczyk, Łukasz Koperski

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 8, 2024

Abstract PET/CT targeting prostate-specific membrane antigen (PSMA) is commonly used in patients with prostate cancer. PSMA has been found other solid tumours, including primary brain tumours. The aim of this study was to evaluate the usefulness [68Ga]Ga-PSMA-11 for preoperative diagnosis and 2-year prognosis. We prospectively screened suspected glioma tumour. qualitative quantitative results were compared histopathological examination. glioblastoma (GBM) diagnostic data or between high-grade (HGG) low-grade (LGG) gliomas. Overall (OS) progression free survival (PFS) analysed. Forty-four met inclusion criteria. Twenty them had positive twenty-four negative scans. sensitivity, specificity, predictive value, value HGG 71.4 (95% confidence interval – 51.3–86.8), 100.0 (79.4–100.0), (83.1–100.0), 66.7 (44.7–84.4), respectively. For differentiation GBM vs non-GBM best parameter tumor-to-background ratio, area under receiver operating characteristic curve 0.81 (0.66–0.96; 42.2) CI; cut-off). Patients scans similar PFS OS HGG. accumulation negatively affected diagnosed GBM. showed optimistic may be prognostic a factor. Registration at www.clinicaltrials.gov 09/06/2023 number NCT05896449

Language: Английский

PSMA-Targeted Radiopharmaceuticals for Prostate Cancer Diagnosis and Therapy DOI
Jorge D. Oldan, Frankis Almaguel, Andrew F. Voter

et al.

The Cancer Journal, Journal Year: 2024, Volume and Issue: 30(3), P. 176 - 184

Published: May 1, 2024

Prostate cancer (PCa) is the most common noncutaneous malignancy in men. Until recent years, accurate imaging of men with newly diagnosed PCa, or recurrent low-volume metastatic disease, was limited. Further, therapeutic options for advanced, metastatic, castration-resistant disease were increasingly limited as a result increasing numbers systemic therapies being combined upfront setting. The advent urea-based, small-molecule inhibitors prostate-specific membrane antigen (PSMA) has partially addressed those shortcomings diagnosis and therapy PCa. On diagnostic side, there are multiple pivotal phase III trials several different agents having demonstrated utility initial staging setting, generally modest sensitivity but very high specificity determining otherwise-occult pelvic nodal involvement. That latter statistic drives scan by allowing interpreters to read while maintaining robust specificity. Other have detection efficiency patients biochemical failure, positive predictive value at lesion level, opening up possible new avenues such metastasis-directed therapy. Beyond aspects PSMA-targeted radiotracers, same urea-based chemical scaffolds can be altered deliver isotopes PCa cells that express PSMA. To date, one agent, when best standard-of-care therapy, an ability improve overall survival, progression-free freedom from skeletal events relative alone who post chemotherapy. Within current milieu, number important future directions including use artificial intelligence better leverage findings, further medicinal chemistry refinements structure may allow improved tumor targeting decreased toxicities, incorporation radionuclides balance efficacy toxicities than nuclides available.

Language: Английский

Citations

2
Hybrid Positron Emission Tomography and Magnetic Resonance Imaging Guided Microsurgical Management of Glial Tumors: Case Series and Review of the Literature DOI Creative Commons
Yusuf Çağlar, Murat Büyüktepe, Emre Yağız Sayacı

et al.

Diagnostics, Journal Year: 2024, Volume and Issue: 14(14), P. 1551 - 1551

Published: July 18, 2024

In this case series, we aimed to report our clinical experience with hybrid positron emission tomography (PET) and magnetic resonance imaging (MRI) navigation in the management of recurrent glial brain tumors. Consecutive neuroglial tumor patients who underwent PET/MRI at preoperative or intraoperative periods were included, whereas non-glial intracranial tumors including metastasis, lymphoma meningioma excluded from study. A total eight (mean age 50.1 ± 11.0 years) suspicion glioma evaluated. Gross resection PET/MRI-positive area was achieved seven patients, one patient diagnosed radiation necrosis, surgery avoided. All survived 1-year follow-up. Five (71.4%) remained free recurrence for entire follow-up period. Two glioblastoma had postoperative sixth eighth months. According results, provides reliable accurate information distinguish necrosis. With help differential diagnosis, may provide gross without harming eloquent areas.

Language: Английский

Citations

2
Prostate-specific membrane antigen expression in intracranial lesions — a review of the primary, metastatic, and nonneoplastic lesions DOI Creative Commons
Kacper Pełka, Aleksandra Bodys-Pełka, Jolanta Kunikowska

et al.

Nuclear Medicine Review, Journal Year: 2023, Volume and Issue: 26(0), P. 134 - 142

Published: Feb. 16, 2023

Prostate-specific membrane antigen (PSMA) is a protein originally discovered in prostate cancer cells. It widely used at all stages of diagnosis. Several studies have highlighted its possible wide application other cancers. This review discusses the potential use positron emission tomography with labelled PSMA for diagnosis or differentiation intracranial lesions. Given numerous reports on usefulness brain tumours glial origin, focus lesions different aetiology.

Language: Английский

Citations

5
Immuno-PET for Glioma Imaging: An Update DOI Creative Commons
Maria Silvia De Feo,

Giorgia Maria Granese,

Miriam Conte

et al.

Applied Sciences, Journal Year: 2024, Volume and Issue: 14(4), P. 1391 - 1391

Published: Feb. 8, 2024

Despite significant advances in glioma diagnosis and treatment, overall outcomes remain suboptimal. Exploring novel therapeutic avenues show promise advancing the field. Theranostics, an evolving discipline integrating therapy, emerges as a particularly auspicious approach. However, unmet need exists for glioma-associated biomarkers theranostic targets. Immuno-positron emission tomography (Immuno-PET), pioneering method uniting PET diagnostic precision with antibody specificity, holds potential identifying cancer-associated biomarkers. This review aims to provide updated overview of immuno-PET applications gliomas. Notably, [44Sc]-CHX-A″-DTPA-Cetuximab-Fab targeting Epidermal Growth Factor Receptor (EGFR) has displayed xenografts, enabling imaging at 4 h post-injection. Similarly, [89Zr]-bevacizumab vascular endothelial growth factor (VEGF) yielded encouraging results preclinical models clinical trial pediatric patients diffuse intrinsic pontine (DIPG). Several cell differentiation markers, including CD146, indicative tumor aggressiveness, CD11b, reflecting tumor-associated myeloid cells (TAMCs), proved effective targets immuno-PET. Additionally, directed prostate-specific antigen (PSMA) demonstrated efficacy neovasculature. While holding precise treatment guidance, challenges persist achieving target specificity selecting suitable radionuclides. Further studies are imperative advance field bridge translational gap from bench bedside.

Language: Английский

Citations

1
PSMA PET in brain metastases: navigating diagnostic challenges– a thorough exploration DOI

Lorenzo Jonghi-Lavarini,

Federico Fallanca,

Gino Pepe

et al.

Clinical and Translational Imaging, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 3, 2024

Language: Английский

Citations

1
Can PSMA-Targeting PET/CT Be a Valuable Instrument to Assess the Presence of Brain Metastases in Lung Cancer Patients? DOI
Sara Dall’Armellina, S. Cauda,

Sergio Duca

et al.

Clinical Nuclear Medicine, Journal Year: 2023, Volume and Issue: 48(6), P. e304 - e306

Published: April 21, 2023

A 78-year-old man with synchronous diagnosis of prostate cancer and lung adenocarcinoma was referred to our institute for staging [ 18 F]F-prostate-specific membrane antigen (PSMA) 1007 PET/CT. In addition the previously known lesion right lung, PSMA-targeted PET/CT highlighted 2 areas abnormal uptake in brain, left frontal temporal lobes. subsequent MRI confirmed lesions observed on Because PSMA-targeting radiopharmaceuticals do not accumulate healthy brain parenchyma, recent literature reported promising performances gliomas metastases from tumors other than cancer, this employment PSMA radioligands needs be further explored.

Language: Английский

Citations

3
Neuro-Oncology and Positron Emission Tomography: “Just Can’t Get Enough” DOI Open Access
Barbara Muoio, Vittoria Espeli, Giorgio Treglia

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(19), P. 4739 - 4739

Published: Sept. 27, 2023

Imaging has a pivotal role in neuro-oncology for the management of primary and secondary brain tumors [...].

Language: Английский

Citations

3
The diagnostic performance of [18F]FET PET/MRI versus [18F]FDG PET/MRI for recurrent glioma: a systematic review and meta-analysis DOI
Huasong Huo, Shurui Shen,

Lanyue Zhang

et al.

Clinical and Translational Imaging, Journal Year: 2023, Volume and Issue: 11(3), P. 285 - 295

Published: May 9, 2023

Language: Английский

Citations

2
68Ga–Prostate-Specific Membrane Antigen PET/CT in Imaging of Hemangiopericytoma DOI
Jolanta Kunikowska, Beata Chrapko

Clinical Nuclear Medicine, Journal Year: 2023, Volume and Issue: 48(9), P. e431 - e433

Published: July 22, 2023

Hemangiopericytoma is a mesenchymal neoplasm that derives from pericytes surrounding the capillaries presenting overexpression of PSMA, which can be source pitfall in 68 Ga-PSMA-11 PET/CT. We reported 2 cases with recurrent hemangiopericytoma grade III high expression Based on performed examination, one them received targeted α-therapy IV injection 225 Ac-PSMA-617.

Language: Английский

Citations

2
Prostate-Specific Membrane Antigen Use in Glioma Management DOI

Joshua D. McBriar,

Neeva Shafiian,

Stephen C. Scharf

et al.

Clinical Nuclear Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: July 3, 2024

Prostate-specific membrane antigen (PSMA) is a membrane-bound metallopeptidase highly expressed in the neovasculature of many solid tumors including gliomas. It particularly enticing therapeutic target due to its ability internalize, thereby delivering radioligands or pharmaceuticals intracellular compartment. Targeting gliomas using PSMA for diagnosis and management has been recent area increased study promise. The purpose this review synthesize current state future directions use histopathologic study, imaging, treatment

Language: Английский

Citations

0